Oxidative stress and peroxisome proliferator-activated receptors: reversing the curse?
Devchand
Pallavi R
PR
Ziouzenkova
Ouliana
O
Plutzky
Jorge
J
D000818:Animals; D005786:Gene Expression Regulation / Q000502:physiology; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D008074:Lipoproteins / Q000502:physiology; D008077:Lipoproteins, LDL / Q000378:metabolism; D019255:NADPH Oxidases / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D009928:Organ Specificity; D018384:Oxidative Stress / Q000187:drug effects; D047493:PPAR alpha / Q000819:agonists / Q000502:physiology; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists / Q000502:physiology*; D017382:Reactive Oxygen Species / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology
D008074:Lipoproteins; D008077:Lipoproteins, LDL; D016328:NF-kappa B; D047493:PPAR alpha; D047492:Peroxisome Proliferator-Activated Receptors; D017382:Reactive Oxygen Species; C099252:oxidized low density lipoprotein; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D019255:NADPH Oxidases